ABO blood group and risk of glioma: a case control study from Serbia

Ana Azanjac Arsić; Svetlana Miletić Drakulić; Katarina Vesić; Gordana Tončev

doi:10.2298/VSP161230104A

Ana Azanjac Arsić University of Kragujevac, Faculty of Medical Sciences, Department of Neurology, Kragujevac, Serbia
Svetlana Miletić Drakulić University of Kragujevac, Faculty of Medical Sciences, Department of Neurology, Kragujevac, Serbia; Clinical Center Kragujevac, Clinic of Neurology, Kragujevac, Serbia
Katarina Vesić University of Kragujevac, Faculty of Medical Sciences, Department of Neurology, Kragujevac, Serbia
Gordana Tončev University of Kragujevac, Faculty of Medical Sciences, Department of Neurology, Kragujevac, Serbia; Clinical Center Kragujevac, Clinic of Neurology, Kragujevac, Serbia

DOI: https://doi.org/10.2298/VSP161230104A

Keywords: glioma;, blood group system;, risk factors.

Abstract

Backgraund/Aim. Gliomas are the most common primary brain tumors and the etiology is unknown. The aim of this study was to investigate possible association between incidence in relation to glioma and certain blood groups. Methods. The case-control study included 100 pathologically confirmed cases of glioma at the Clinical centar of Kragujevac, Serbia, between 2014 and 2015, and 200 age- and sex-matched controls without malignant diseases in personal and family history at the same institution. After signing the informed consent, all patients filled out an epidemiological questionnaire. Results. In the analysis comparing the glioma patients with the control group, a significant association (p < 0.0005) was observed in relation to the blood group AB. Furthermore, it was not observed a significant association in relation to the blood group A (p = 0.070), blood group B (p = 0.256), blood group O (p = 0.768) among the compared groups. Also, in the analysis comparing glioma patients with the control group, a significant association was observed in relation to the years spent in hometown (p = 0.035), changing the place of residence (p = 0.007), the body weight (p = 0.002) and the body mass index (p < 0.0005). Univariate binary logistic regression showed that higher number of years spent in the hometown [odds ratio (OR) 1.011 95% confidence interval (Cl) 1.000–1.023; p = 0.043], increased body weight (OR 0.976 95% Cl 0.959–0.993, p = 0.006) and increased body mass index (OR 0.898 95% Cl 0.839–0.961; p = 0.002) increase the risk of glioma. However, a change of the residence decreases the risk of glioma (OR 0.327 95% Cl 0.147–0.727; p = 0.006). Univariate binary logistic regression analysis revealed that the individuals with group AB were at 3.5-fold increased risk of developing glioma compared to the individuals with other ABO blood groups (OR 3,429 95% Cl 1,83–6,41; p < 0.0005). Also, there was more male patients with glioma with the blood group AB (p = 0.001). Conclusion. In a present study, we demonstrate that individuals with the group AB have an increased risk of developing glioma.

Author Biography

Ana Azanjac Arsić, University of Kragujevac, Faculty of Medical Sciences, Department of Neurology, Kragujevac, Serbia

doktor medicine

saradnik u nastavi na Katedri za neurologiju

References

Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: A “state of the science” review. Neuro Oncol 2014; 16(7): 896–913.

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol 2015; 17 Suppl 4: iv1–iv62.

Malmer B, Adatto P, Armstrong G, Barnholtz-Sloan J, Bernstein JL, Claus E, et al. GLIOGENE an International Consortium to Understand Familial Glioma. Cancer Epidemiol Bi-omarkers Prev 2007; 16(9): 1730–4.

Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il'yasova D, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008; 113(7 Suppl): 1953–68.

Yates PO, Pearce KM. Recent change in blood-group distribu-tion of astrocytomas. Lancet 1960; 1(7117): 194–5.

Selvestrone B, Cooper DR. ABO blood group and astrocytomas. J Neurosurg 1961; 18: 602–4.

Yates PO. Malgnant glioma and ABO blood group. Br Med J 1964; 1(5378): 310.

Strang RR, Tovi D, Lopez J. Astrocytomas and the ABO blood groups. J Med Genet 1966; 3: 274–5.

Akhtar K, Mehdi G, Sherwani R, Sofi L. Relationship between various cancers and ABO blood groups: A Northern India ex-perience. Int J Pathol 2010; 13(1): 1–4.

Akca Z, Mutlu H, Erden A, Buyukcelik A, Sezer Y, Inal A. The relationship between ABO blood group and glioblastoma mul-tiforme. Med Sci 2014; 3(4): 1639–47.

Zhang B, He N, Huang Y, Song F, Chen K. ABO blood groups and risk of cancer: A systematic review and meta-analysis. Asian Pac J Cancer Prev 2014; 15(11): 4643–50.

Allouh MZ, Barbarawi AM, Hiasat MY, Al-Qaralleh MA, Ab-abneh EI. Glioblastoma and ABO blood groups: Further evi-dence of an association between the distribution of blood group antigens and brain tumours. Blood Transfus 2017; 15(6): 543–7.

Landsteiner K. Über Agglutinationserscheinungen normalen menschlichen Blutes. In: Harper PS, editor. Landmarks in Medical Genetics. Oxford: Oxford University Press; 1901. p. 112–4.

Franchini M, Liumbruno GM. ABO blood group: Old dogma, new perspectives. Clin Chem Lab Med 2013; 51(8): 1545–53.

Liumbruno GM, Franchini M. Beyond immunohaematology: The role of the ABO blood group in human diseases. Blood Transfus 2013; 11(4): 491–9.

Hsiao L, Liu N, You S, Hwang L. ABO blood group and the risk of cancer among middle-aged people in Taiwan. Asia Pac J Clin Oncol 2015; 11(4): e31–6.

Jovanović SS, Veljković DK. Immunobiological and clinical sig-nificance of blood groups. Beograd: Intra Net Communica-tion; 2009. (Serbian)

Louis DN, Perry A, Reifenberger G, Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol 2016; 131(6): 803–20.

Franchini M, Lippi G. The intriguing relationship between the ABO blood group, cardiovascular disease, and cancer. BMC Med 2015; 13: 7.

Prieto PA, Smith DF. A new ganglioside in human meconium defected by antiserum against the human milk sialylohigosac-charide 2S-tetrasaccharide b. Archives of Biochemistry and Biophysics 1985; 241(1): 281–9.